Rafferty Asset Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Rafferty Asset Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-208,207	Closed	-$8M	–	1114
2023 Q2	$8M	Buy	208,207 +27,133	+15%	+$697K	0.05%	279
2023 Q1	$4.19M	Buy	181,074 +7,063	+4%	+$168K	0.03%	424
2022 Q4	$4.56M	Buy	174,011 +30,893	+22%	+$684K	0.04%	391
2022 Q3	$2.81M	Buy	143,118 +103,816	+264%	+$2.08M	0.03%	433
2022 Q2	$687K	Sell	39,302 -40,037	-50%	-$628K	0.01%	749
2022 Q1	$1.3M	Buy	79,339 +13,975	+21%	+$190K	0.01%	729
2021 Q4	$1.07M	Buy	65,364 +19,209	+42%	+$273K	0.01%	837
2021 Q3	$589K	Buy	46,155 +20,692	+81%	+$272K	﹤0.01%	1004
2021 Q2	$360K	Buy	+25,463	New	+$407K	﹤0.01%	1137

Rafferty Asset Management's KDNY Position: Q3 2023 in Review

Rafferty Asset Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 208,207 shares — an estimated $8M sold.

Rafferty Asset Management first reported a position in KDNY in Q2 2021 and held it in 9 quarters. The position peaked at $8M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Rafferty Asset Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Rafferty Asset Management sold 208,207 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $8M.
Rafferty Asset Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2021 and held it in 9 quarters.
Rafferty Asset Management's Chinook Therapeutics, Inc. Common Stock position peaked at $8M in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Rafferty Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.